BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  GLP-1

  Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval

  The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

  December 23, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Approvals

  Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down

  The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.

  December 23, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Regulatory

  5 Companies That Celebrated First Approvals in 2024

  Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.

  December 23, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Neuroscience

  2024 Highlights the Rollercoaster That Is Neuro

  This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.

  December 23, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  GLP-1

  7 Indications for GLP-1s Beyond Weight Loss

  Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including cancer, addiction and neurodegenerative diseases.

  December 23, 2024

   · 

  11 min read

   · 

  Tristan Manalac
• 

  Executive Appointments

  After Month of Bad News, Applied Shuffles Leadership, Lays Out Uncertain Path for Rare Disease Drug

  Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct during a clinical trial, the biotech’s CEO has stepped aside.
  

  December 23, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Venture Capitalists

  To Attract VC Dollars in 2025, Biopharma Must Bring the Data: Pitchbook

  High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk, Pitchbook said in its 2025 outlook.

  December 23, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

  December 23, 2024

   · 

  3 min read
• Press Releases

  Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

  December 23, 2024

   · 

  5 min read
• Press Releases

  Ellipses Launches Pioneering Clinical Trial Programme in Middle East

  December 23, 2024

   · 

  4 min read